The medicinal chemistry of novel iron chelators for the treatment of cancer.
about
Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugsMetal binding ability of curcumin derivatives: a theoretical vs. experimental approach.Effect of silibinin in reducing inflammatory pathways in in vitro and in vivo models of infection-induced preterm birth.Synthesis, DNA Binding, and Antiproliferative Activity of Novel Acridine-Thiosemicarbazone DerivativesTargeting iron assimilation to develop new antibacterials.Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.Iron chelation: a potential therapeutic strategy in oesophageal cancer.Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.Iron in multiple myeloma.Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.Metal-mediated DNA damage and cell death: mechanisms, detection methods, and cellular consequences.The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα.Heterocyclic dithiocarbazate iron chelators: Fe coordination chemistry and biological activity.A novel method for assessing the role of iron and its functional chelation in fibrin fibril formation: the use of scanning electron microscopy.Silibinin Inhibits Neutrophilic Inflammation and Mucus Secretion Induced by Cigarette Smoke via Suppression of ERK-SP1 Pathway.In vitro antiproliferative study of novel adamantyl pyridin-4-ones.Inhibition of prostate cancer proliferation by Deferiprone.Human apo-lactoferrin as a physiological mimetic of hypoxia stabilizes hypoxia-inducible factor-1 alpha.Partial conversion of thioamide into nitrile in a copper(II) complex of 2,6-diacetylpyridine bis(thiosemicarbazone), a drug prototype for Alzheimer's disease.Anti-proliferative effect of Fe(III) complexed with 1-(2-hydroxy-3-methoxybenzaldehyde)-4-aminosalicylhydrazone in HepG2 cells.Gallium(iii) and iron(iii) complexes of quinolone antimicrobials.
P2860
Q28539989-FB2A9EFC-7F50-4B95-91CD-ADFA0FC8F922Q30588369-795AF393-3866-4CAC-AF30-AEB715D0F4F7Q35125295-7A10D907-F2C5-468F-9FEA-CE01D6BDFE5AQ35813958-B3DC9560-4288-4A19-BB92-DB35D3377349Q36211648-BB7362B4-C874-4A99-AB3B-A5793A45D0DDQ36568915-1E7F1AF6-11D8-48B3-8D76-D8BC4220E70BQ36681739-0FEC254B-58B5-4F4B-BDDD-37353C83F388Q36681744-DB19985B-98AB-4640-A82C-AAF6EBE7D3E0Q37089777-C9317FCE-AF0A-43E4-9C02-1B1D808C3022Q37460101-C173ED3F-A05B-46C2-9AF7-A96ED2AF2896Q38208675-8E55F54B-F070-4586-AA3B-1E48857F74F2Q39364743-66D494F1-88B0-4041-B2C6-35AFD33B269BQ39391002-B63D90F0-30AB-4BF0-B61E-4CBDE1625D05Q44286743-EE400D68-11D5-40B5-A105-AA0F04F239F6Q46509706-BE57D6E8-FC8B-40F0-AC3F-7CB86D705B21Q48147543-5BA6D03D-8A14-4051-B1D8-2E580808878EQ48150564-5D8892D5-0626-4539-8A9C-E27D96697442Q48365992-847400E4-F71D-459A-9DE2-4357AA9D6140Q53477033-6B42E560-FF2B-4BA3-9CC1-010B7E8B6BB6Q53554686-C17D2829-C4F5-470A-95D2-962531E2C1F0Q54243572-A574521D-CA3B-4913-B682-19B346CD4BE7
P2860
The medicinal chemistry of novel iron chelators for the treatment of cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The medicinal chemistry of novel iron chelators for the treatment of cancer.
@en
The medicinal chemistry of novel iron chelators for the treatment of cancer.
@nl
type
label
The medicinal chemistry of novel iron chelators for the treatment of cancer.
@en
The medicinal chemistry of novel iron chelators for the treatment of cancer.
@nl
prefLabel
The medicinal chemistry of novel iron chelators for the treatment of cancer.
@en
The medicinal chemistry of novel iron chelators for the treatment of cancer.
@nl
P50
P1476
The medicinal chemistry of novel iron chelators for the treatment of cancer
@en
P2093
Phillip C Sharpe
P304
P356
10.2174/156802611794785190
P50
P577
2011-01-01T00:00:00Z